Shots:

• The P-III (EQUATOR) study evaluates the efficacy and safety of itolizumab vs PBO in a ratio (1:1) in 200 adult and adolescent patients with Grade II or III-IV aGVHD with lower GI involvement in combination with high doses of corticosteroids at North America, Europe, Asia, and Australia. The study is based on the (EQUATE) study
• The primary objective of the study is CR rate @ Day 29 & will evaluate to achieve early disease response while the 2EPs objective is ORR @ Day 29 and durability of CR rate from Day 29 through Day 99 & will evaluate DoR, corticosteroid use, survival outcomes & chronic GVHD incidence
• Itolizumab is an anti-CD6 mAb that selectively targets the CD6-ALCAM pathway. The therapy has received FTD & ODD from the US FDA for the treatment of patients with aGVHD

Ref: Equillium | Image: Equillium